| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Critical Care | 19 | 2018 | 658 | 1.830 |
Why?
|
| Pregnancy Complications | 9 | 2018 | 514 | 1.600 |
Why?
|
| Critical Illness | 9 | 2021 | 601 | 1.240 |
Why?
|
| Respiration, Artificial | 14 | 2021 | 473 | 1.220 |
Why?
|
| Asthma | 12 | 2008 | 756 | 1.110 |
Why?
|
| Intensive Care Units | 14 | 2016 | 493 | 1.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2017 | 604 | 0.730 |
Why?
|
| Burnout, Professional | 2 | 2018 | 118 | 0.620 |
Why?
|
| Snoring | 1 | 2018 | 18 | 0.610 |
Why?
|
| Sepsis | 6 | 2021 | 482 | 0.610 |
Why?
|
| Nursing Staff, Hospital | 3 | 2018 | 60 | 0.590 |
Why?
|
| Job Satisfaction | 1 | 2018 | 81 | 0.560 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2018 | 75 | 0.560 |
Why?
|
| Plant Poisoning | 1 | 2016 | 1 | 0.530 |
Why?
|
| Euphorbiaceae | 1 | 2016 | 2 | 0.530 |
Why?
|
| Lactoferrin | 2 | 2015 | 78 | 0.510 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2015 | 104 | 0.510 |
Why?
|
| Hypokalemia | 1 | 2016 | 42 | 0.510 |
Why?
|
| Disease Management | 2 | 2017 | 532 | 0.480 |
Why?
|
| Respiratory Insufficiency | 5 | 2017 | 226 | 0.480 |
Why?
|
| Endocrine System Diseases | 2 | 2006 | 43 | 0.470 |
Why?
|
| Helium | 2 | 2005 | 10 | 0.450 |
Why?
|
| Respiratory Function Tests | 6 | 2021 | 199 | 0.450 |
Why?
|
| Infertility | 2 | 2006 | 78 | 0.450 |
Why?
|
| Postpartum Period | 1 | 2015 | 216 | 0.440 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2014 | 30 | 0.440 |
Why?
|
| Bronchodilator Agents | 3 | 2005 | 151 | 0.420 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2014 | 145 | 0.420 |
Why?
|
| India | 8 | 2016 | 212 | 0.420 |
Why?
|
| Plasma Exchange | 1 | 2014 | 84 | 0.420 |
Why?
|
| Stress, Psychological | 1 | 2018 | 560 | 0.410 |
Why?
|
| Delivery, Obstetric | 1 | 2015 | 252 | 0.410 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 460 | 0.390 |
Why?
|
| Female | 56 | 2022 | 66998 | 0.380 |
Why?
|
| Humans | 93 | 2022 | 125667 | 0.380 |
Why?
|
| Physicians | 2 | 2018 | 589 | 0.370 |
Why?
|
| Glucocorticoids | 1 | 2014 | 383 | 0.370 |
Why?
|
| Oxygen | 4 | 2005 | 557 | 0.370 |
Why?
|
| Adult | 39 | 2021 | 29734 | 0.350 |
Why?
|
| Smoking | 4 | 2006 | 1051 | 0.350 |
Why?
|
| Shock, Septic | 7 | 2015 | 147 | 0.350 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2022 | 114 | 0.340 |
Why?
|
| Pregnancy | 13 | 2020 | 7223 | 0.330 |
Why?
|
| Acute Kidney Injury | 2 | 2016 | 638 | 0.320 |
Why?
|
| Lung Diseases | 3 | 2010 | 384 | 0.310 |
Why?
|
| Pneumocystis | 3 | 1997 | 11 | 0.300 |
Why?
|
| Respiratory Sounds | 1 | 2008 | 70 | 0.300 |
Why?
|
| Global Health | 2 | 2010 | 567 | 0.290 |
Why?
|
| Middle Aged | 35 | 2022 | 27000 | 0.290 |
Why?
|
| Health Promotion | 1 | 2010 | 389 | 0.280 |
Why?
|
| Vasodilator Agents | 3 | 2017 | 206 | 0.280 |
Why?
|
| Hypoxia | 2 | 2020 | 250 | 0.270 |
Why?
|
| Vocal Cords | 2 | 2006 | 66 | 0.270 |
Why?
|
| Lung Diseases, Obstructive | 2 | 1998 | 34 | 0.260 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 677 | 0.260 |
Why?
|
| Nervous System Diseases | 2 | 2012 | 376 | 0.260 |
Why?
|
| Aerosol Propellants | 1 | 2005 | 2 | 0.250 |
Why?
|
| Male | 40 | 2022 | 61776 | 0.240 |
Why?
|
| Albuterol | 1 | 2005 | 52 | 0.240 |
Why?
|
| Tobacco Use Disorder | 1 | 2006 | 91 | 0.240 |
Why?
|
| Nitric Oxide | 3 | 2009 | 494 | 0.240 |
Why?
|
| Withholding Treatment | 1 | 2005 | 69 | 0.230 |
Why?
|
| Hypnotics and Sedatives | 2 | 2021 | 133 | 0.230 |
Why?
|
| Family Health | 1 | 2005 | 259 | 0.230 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 130 | 0.220 |
Why?
|
| Terminal Care | 1 | 2005 | 112 | 0.220 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2006 | 217 | 0.210 |
Why?
|
| Pneumonia, Pneumocystis | 4 | 1997 | 37 | 0.210 |
Why?
|
| Skin Diseases | 1 | 2004 | 130 | 0.210 |
Why?
|
| Ipratropium | 1 | 2002 | 7 | 0.200 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2004 | 150 | 0.200 |
Why?
|
| Internal Medicine | 2 | 2008 | 150 | 0.190 |
Why?
|
| Hospitalization | 4 | 2022 | 1790 | 0.180 |
Why?
|
| Prospective Studies | 10 | 2014 | 6171 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 1700 | 0.180 |
Why?
|
| Aged | 21 | 2022 | 19900 | 0.180 |
Why?
|
| Lung Transplantation | 2 | 2022 | 322 | 0.180 |
Why?
|
| Carbon Dioxide | 5 | 2009 | 279 | 0.180 |
Why?
|
| Propofol | 1 | 2021 | 44 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2004 | 339 | 0.180 |
Why?
|
| Emigrants and Immigrants | 1 | 2022 | 144 | 0.170 |
Why?
|
| Acute Disease | 6 | 2017 | 1111 | 0.170 |
Why?
|
| Conscious Sedation | 1 | 2021 | 58 | 0.170 |
Why?
|
| Fluorescent Antibody Technique, Direct | 2 | 1997 | 12 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2014 | 206 | 0.170 |
Why?
|
| Prone Position | 1 | 2020 | 32 | 0.170 |
Why?
|
| Dexmedetomidine | 1 | 2021 | 49 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2021 | 378 | 0.170 |
Why?
|
| Pregnancy Outcome | 4 | 2014 | 595 | 0.170 |
Why?
|
| Double-Blind Method | 6 | 2021 | 1636 | 0.170 |
Why?
|
| Patient Positioning | 1 | 2020 | 54 | 0.170 |
Why?
|
| Algorithms | 4 | 2020 | 1632 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2005 | 608 | 0.170 |
Why?
|
| Bronchi | 3 | 2005 | 99 | 0.160 |
Why?
|
| Positive-Pressure Respiration | 7 | 2020 | 84 | 0.160 |
Why?
|
| Heat Stress Disorders | 1 | 1999 | 10 | 0.160 |
Why?
|
| Risk Adjustment | 1 | 1999 | 58 | 0.160 |
Why?
|
| Vibration | 2 | 2008 | 32 | 0.150 |
Why?
|
| Infusions, Parenteral | 2 | 2013 | 100 | 0.150 |
Why?
|
| Risk Factors | 11 | 2014 | 10340 | 0.150 |
Why?
|
| APACHE | 3 | 2015 | 53 | 0.150 |
Why?
|
| Spirometry | 3 | 2006 | 73 | 0.150 |
Why?
|
| Registries | 2 | 2022 | 1436 | 0.150 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 2918 | 0.150 |
Why?
|
| Diagnosis, Differential | 7 | 2017 | 1901 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2008 | 95 | 0.140 |
Why?
|
| Bronchial Hyperreactivity | 2 | 1996 | 38 | 0.140 |
Why?
|
| Breathing Exercises | 1 | 2017 | 7 | 0.140 |
Why?
|
| Benzenesulfonates | 1 | 1997 | 12 | 0.140 |
Why?
|
| Prognosis | 7 | 2011 | 4690 | 0.140 |
Why?
|
| Yoga | 1 | 2017 | 12 | 0.140 |
Why?
|
| Lung | 7 | 2020 | 1496 | 0.140 |
Why?
|
| Angioedema | 1 | 1997 | 22 | 0.140 |
Why?
|
| Pulmonary Ventilation | 1 | 1997 | 29 | 0.140 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 31 | 0.140 |
Why?
|
| Prevalence | 6 | 2014 | 2467 | 0.130 |
Why?
|
| Exercise Tolerance | 1 | 2017 | 85 | 0.130 |
Why?
|
| Equipment Design | 2 | 2008 | 599 | 0.130 |
Why?
|
| Fluid Therapy | 1 | 2017 | 129 | 0.130 |
Why?
|
| Respiratory Tract Diseases | 1 | 1997 | 75 | 0.130 |
Why?
|
| Program Evaluation | 2 | 2010 | 443 | 0.130 |
Why?
|
| Nitric Oxide Synthase | 3 | 2004 | 187 | 0.130 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 262 | 0.120 |
Why?
|
| Medical Staff, Hospital | 1 | 1996 | 93 | 0.120 |
Why?
|
| Hospital Mortality | 4 | 2013 | 1026 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 225 | 0.120 |
Why?
|
| Hypertension, Pregnancy-Induced | 2 | 2014 | 74 | 0.120 |
Why?
|
| Arginine | 2 | 2009 | 336 | 0.120 |
Why?
|
| Sputum | 1 | 1996 | 106 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 239 | 0.120 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 136 | 0.120 |
Why?
|
| Specimen Handling | 1 | 1996 | 142 | 0.120 |
Why?
|
| Isoniazid | 1 | 1995 | 62 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 377 | 0.120 |
Why?
|
| Hypotension | 2 | 2007 | 187 | 0.120 |
Why?
|
| Trachea | 3 | 1997 | 203 | 0.110 |
Why?
|
| Injections, Intravenous | 1 | 2014 | 249 | 0.110 |
Why?
|
| Cerebrospinal Fluid | 1 | 2014 | 94 | 0.110 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2014 | 57 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2012 | 275 | 0.110 |
Why?
|
| Contrast Media | 1 | 1997 | 480 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 1996 | 447 | 0.110 |
Why?
|
| Antitubercular Agents | 1 | 1995 | 250 | 0.100 |
Why?
|
| Administration, Inhalation | 3 | 2005 | 180 | 0.100 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 148 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2014 | 174 | 0.100 |
Why?
|
| Nebulizers and Vaporizers | 1 | 1993 | 57 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 265 | 0.100 |
Why?
|
| Intubation, Intratracheal | 3 | 1997 | 287 | 0.100 |
Why?
|
| Adolescent | 9 | 2016 | 19441 | 0.100 |
Why?
|
| Placebos | 1 | 2013 | 241 | 0.100 |
Why?
|
| omega-N-Methylarginine | 2 | 2004 | 12 | 0.090 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 222 | 0.090 |
Why?
|
| Postoperative Care | 4 | 1988 | 301 | 0.090 |
Why?
|
| High-Frequency Jet Ventilation | 2 | 1988 | 3 | 0.090 |
Why?
|
| Suction | 2 | 1997 | 55 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2010 | 1520 | 0.090 |
Why?
|
| Societies, Medical | 2 | 2010 | 699 | 0.090 |
Why?
|
| Pneumonia, Lipid | 1 | 1991 | 1 | 0.090 |
Why?
|
| Lung Volume Measurements | 2 | 2005 | 75 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2013 | 12420 | 0.090 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2010 | 37 | 0.090 |
Why?
|
| Laryngoscopy | 2 | 2006 | 151 | 0.090 |
Why?
|
| Decision Trees | 2 | 2004 | 50 | 0.090 |
Why?
|
| Ibuprofen | 1 | 2010 | 40 | 0.080 |
Why?
|
| Amikacin | 1 | 2009 | 24 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1410 | 0.080 |
Why?
|
| Forecasting | 1 | 2010 | 354 | 0.080 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2009 | 87 | 0.080 |
Why?
|
| Aerosols | 3 | 2009 | 65 | 0.080 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 30 | 0.080 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2008 | 6 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3439 | 0.070 |
Why?
|
| Lung Neoplasms | 3 | 2010 | 1659 | 0.070 |
Why?
|
| United States | 7 | 2010 | 10942 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 307 | 0.070 |
Why?
|
| Citrulline | 1 | 2009 | 111 | 0.070 |
Why?
|
| Fever | 1 | 2010 | 299 | 0.070 |
Why?
|
| Monitoring, Physiologic | 3 | 2005 | 377 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 259 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 392 | 0.070 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 3745 | 0.070 |
Why?
|
| Incidence | 3 | 2006 | 3155 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 1990 | 180 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2022 | 16417 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1106 | 0.070 |
Why?
|
| Equipment Failure | 2 | 1984 | 121 | 0.070 |
Why?
|
| Radionuclide Imaging | 2 | 2005 | 150 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 1996 | 149 | 0.070 |
Why?
|
| Cross Infection | 1 | 2009 | 326 | 0.070 |
Why?
|
| Laryngeal Diseases | 2 | 1997 | 32 | 0.070 |
Why?
|
| Glottis | 1 | 2006 | 31 | 0.060 |
Why?
|
| Young Adult | 3 | 2014 | 9093 | 0.060 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2005 | 9 | 0.060 |
Why?
|
| Receptors, Leukotriene | 1 | 2005 | 6 | 0.060 |
Why?
|
| Biological Availability | 1 | 2005 | 137 | 0.060 |
Why?
|
| Hospitals, Public | 1 | 2005 | 41 | 0.060 |
Why?
|
| Mucous Membrane | 1 | 2005 | 89 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 2 | 2004 | 137 | 0.060 |
Why?
|
| Airway Resistance | 1 | 2005 | 36 | 0.060 |
Why?
|
| Central Venous Pressure | 1 | 2005 | 26 | 0.060 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2005 | 50 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2005 | 93 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2010 | 526 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2021 | 543 | 0.060 |
Why?
|
| Airway Obstruction | 2 | 1997 | 165 | 0.060 |
Why?
|
| Hemodynamics | 7 | 2004 | 853 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2005 | 111 | 0.060 |
Why?
|
| Phosphorus | 1 | 1984 | 56 | 0.060 |
Why?
|
| Leukocytes | 1 | 2005 | 212 | 0.060 |
Why?
|
| Hyperthermia, Induced | 1 | 1984 | 54 | 0.060 |
Why?
|
| Pulmonary Edema | 1 | 1984 | 47 | 0.050 |
Why?
|
| Observer Variation | 1 | 2005 | 299 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1114 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2005 | 141 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2008 | 409 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2014 | 3470 | 0.050 |
Why?
|
| Tidal Volume | 2 | 2017 | 39 | 0.050 |
Why?
|
| Cross-Over Studies | 2 | 2002 | 315 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 226 | 0.050 |
Why?
|
| Lung Injury | 1 | 2005 | 122 | 0.050 |
Why?
|
| Polysomnography | 2 | 2014 | 146 | 0.050 |
Why?
|
| Iron-Dextran Complex | 1 | 1982 | 3 | 0.050 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 1982 | 8 | 0.050 |
Why?
|
| Cardiovascular System | 1 | 2004 | 107 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2008 | 1186 | 0.050 |
Why?
|
| Starch | 1 | 1982 | 25 | 0.050 |
Why?
|
| Developing Countries | 1 | 2004 | 271 | 0.050 |
Why?
|
| Brain Death | 1 | 1983 | 61 | 0.050 |
Why?
|
| Respiratory Therapy | 2 | 2011 | 21 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 1990 | 881 | 0.050 |
Why?
|
| Shock, Hemorrhagic | 1 | 1982 | 54 | 0.050 |
Why?
|
| Respiration | 2 | 1996 | 122 | 0.050 |
Why?
|
| Physical Examination | 2 | 2011 | 159 | 0.050 |
Why?
|
| Communication | 1 | 2005 | 517 | 0.050 |
Why?
|
| Gestational Age | 1 | 2005 | 1168 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 1982 | 334 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 91 | 0.040 |
Why?
|
| Infusions, Intravenous | 4 | 2010 | 556 | 0.040 |
Why?
|
| Ventilator Weaning | 1 | 2000 | 27 | 0.040 |
Why?
|
| Caregivers | 1 | 2005 | 578 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1997 | 320 | 0.040 |
Why?
|
| Disease Progression | 1 | 2006 | 2089 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 1997 | 1070 | 0.040 |
Why?
|
| Heat Stroke | 1 | 1999 | 4 | 0.040 |
Why?
|
| Acclimatization | 1 | 1999 | 14 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2000 | 89 | 0.040 |
Why?
|
| Body Temperature Regulation | 1 | 1999 | 40 | 0.040 |
Why?
|
| International Cooperation | 1 | 1999 | 158 | 0.040 |
Why?
|
| Fatal Outcome | 2 | 1997 | 359 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 1998 | 75 | 0.040 |
Why?
|
| Hemoptysis | 2 | 1995 | 22 | 0.040 |
Why?
|
| Leucine | 2 | 2009 | 310 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1075 | 0.040 |
Why?
|
| Electroencephalography | 1 | 1983 | 866 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1533 | 0.040 |
Why?
|
| Time Factors | 4 | 1999 | 6351 | 0.040 |
Why?
|
| Rhinoscleroma | 1 | 1997 | 4 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 1995 | 443 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 290 | 0.030 |
Why?
|
| Child | 7 | 2003 | 24559 | 0.030 |
Why?
|
| Fatty Alcohols | 1 | 1996 | 5 | 0.030 |
Why?
|
| Phosphorylcholine | 1 | 1996 | 26 | 0.030 |
Why?
|
| Asthma, Exercise-Induced | 1 | 1996 | 1 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5195 | 0.030 |
Why?
|
| Fixatives | 1 | 1996 | 14 | 0.030 |
Why?
|
| Pulmonary Surfactants | 1 | 1996 | 43 | 0.030 |
Why?
|
| Climate | 1 | 1996 | 20 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 729 | 0.030 |
Why?
|
| Skin | 1 | 1999 | 519 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 1997 | 240 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 585 | 0.030 |
Why?
|
| Vocal Cord Paralysis | 1 | 1997 | 67 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 274 | 0.030 |
Why?
|
| Fetal Monitoring | 1 | 1996 | 56 | 0.030 |
Why?
|
| Pyridoxine | 1 | 1995 | 14 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1997 | 223 | 0.030 |
Why?
|
| Famotidine | 1 | 1995 | 9 | 0.030 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1995 | 37 | 0.030 |
Why?
|
| Gastric Acid | 1 | 1995 | 56 | 0.030 |
Why?
|
| Bronchiectasis | 1 | 1995 | 23 | 0.030 |
Why?
|
| Career Choice | 1 | 1996 | 148 | 0.030 |
Why?
|
| Drug Overdose | 1 | 1995 | 66 | 0.030 |
Why?
|
| Takayasu Arteritis | 1 | 1994 | 13 | 0.030 |
Why?
|
| Hydrostatic Pressure | 2 | 2005 | 8 | 0.030 |
Why?
|
| Patient Selection | 1 | 1998 | 701 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1996 | 240 | 0.030 |
Why?
|
| Acidosis | 1 | 1995 | 93 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1995 | 460 | 0.030 |
Why?
|
| Social Support | 1 | 1996 | 346 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1994 | 108 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 1996 | 2060 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2004 | 171 | 0.030 |
Why?
|
| Bed Occupancy | 1 | 1993 | 3 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 2899 | 0.030 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1993 | 14 | 0.030 |
Why?
|
| Respiratory Therapy Department, Hospital | 1 | 1993 | 2 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1997 | 348 | 0.030 |
Why?
|
| Amiodarone | 1 | 1993 | 45 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1993 | 74 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2005 | 8249 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 2 | 2006 | 507 | 0.020 |
Why?
|
| Radiography | 2 | 1993 | 824 | 0.020 |
Why?
|
| Mineral Oil | 1 | 1991 | 4 | 0.020 |
Why?
|
| Self Medication | 1 | 1991 | 23 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2009 | 3312 | 0.020 |
Why?
|
| Life Support Care | 1 | 2011 | 48 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1273 | 0.020 |
Why?
|
| Airway Management | 1 | 2011 | 62 | 0.020 |
Why?
|
| Seizures | 1 | 1995 | 872 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1991 | 122 | 0.020 |
Why?
|
| Intubation | 1 | 2009 | 17 | 0.020 |
Why?
|
| Constipation | 1 | 1991 | 114 | 0.020 |
Why?
|
| Shock | 1 | 2011 | 90 | 0.020 |
Why?
|
| Carbon Isotopes | 1 | 2009 | 277 | 0.020 |
Why?
|
| Texas | 2 | 1998 | 3588 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 2178 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 2 | 1987 | 258 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2011 | 348 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 787 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2008 | 79 | 0.020 |
Why?
|
| Pressure | 1 | 1988 | 131 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2011 | 389 | 0.020 |
Why?
|
| Workload | 1 | 2008 | 147 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 196 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1333 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6607 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2011 | 318 | 0.020 |
Why?
|
| Nitrates | 1 | 2006 | 29 | 0.020 |
Why?
|
| Nitrogen Isotopes | 1 | 2006 | 63 | 0.020 |
Why?
|
| Nitrites | 1 | 2006 | 49 | 0.020 |
Why?
|
| Cardiomyopathies | 1 | 2011 | 501 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 1992 | 3080 | 0.020 |
Why?
|
| RNA Probes | 1 | 2005 | 30 | 0.020 |
Why?
|
| Length of Stay | 2 | 2007 | 1313 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2005 | 55 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 258 | 0.010 |
Why?
|
| Cohort Studies | 2 | 2008 | 4843 | 0.010 |
Why?
|
| Mast Cells | 1 | 2005 | 78 | 0.010 |
Why?
|
| Transducers | 1 | 2005 | 24 | 0.010 |
Why?
|
| Homeostasis | 1 | 2009 | 705 | 0.010 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 1984 | 9 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2005 | 171 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2005 | 471 | 0.010 |
Why?
|
| Glucose | 1 | 2009 | 878 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2005 | 329 | 0.010 |
Why?
|
| Eosinophils | 1 | 2005 | 118 | 0.010 |
Why?
|
| Inservice Training | 1 | 2005 | 56 | 0.010 |
Why?
|
| Bloodletting | 1 | 1984 | 5 | 0.010 |
Why?
|
| Tourniquets | 1 | 1984 | 10 | 0.010 |
Why?
|
| Electrolytes | 1 | 1984 | 53 | 0.010 |
Why?
|
| Bicarbonates | 1 | 1984 | 98 | 0.010 |
Why?
|
| Osmotic Pressure | 1 | 1984 | 22 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 1984 | 22 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 1984 | 29 | 0.010 |
Why?
|
| Nitroprusside | 1 | 1984 | 47 | 0.010 |
Why?
|
| Dobutamine | 1 | 1984 | 56 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2005 | 128 | 0.010 |
Why?
|
| Digoxin | 1 | 1984 | 43 | 0.010 |
Why?
|
| Capillary Permeability | 1 | 1984 | 76 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1997 | 14106 | 0.010 |
Why?
|
| Morphine | 1 | 1984 | 83 | 0.010 |
Why?
|
| Proteins | 1 | 2009 | 1038 | 0.010 |
Why?
|
| Renin | 1 | 1983 | 93 | 0.010 |
Why?
|
| Body Weight | 1 | 1988 | 990 | 0.010 |
Why?
|
| Posture | 1 | 1984 | 154 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 322 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1122 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1816 | 0.010 |
Why?
|
| Diuretics | 1 | 1984 | 171 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2004 | 121 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 381 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 208 | 0.010 |
Why?
|
| HIV Infections | 1 | 1995 | 1899 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2003 | 48 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 1990 | 856 | 0.010 |
Why?
|
| Emergencies | 1 | 1984 | 172 | 0.010 |
Why?
|
| Hospital Bed Capacity | 2 | 1993 | 25 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 871 | 0.010 |
Why?
|
| Anemia, Hypochromic | 1 | 1982 | 7 | 0.010 |
Why?
|
| Christianity | 1 | 1982 | 14 | 0.010 |
Why?
|
| Oxygen Consumption | 2 | 1999 | 305 | 0.010 |
Why?
|
| Dopamine | 1 | 1984 | 283 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 534 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 718 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 729 | 0.010 |
Why?
|
| Bronchial Fistula | 1 | 1982 | 22 | 0.010 |
Why?
|
| Pleural Diseases | 1 | 1982 | 28 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 2003 | 153 | 0.010 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1982 | 53 | 0.010 |
Why?
|
| Fistula | 1 | 1982 | 49 | 0.010 |
Why?
|
| Biopsy | 1 | 2005 | 1241 | 0.010 |
Why?
|
| Macrophages | 1 | 2005 | 627 | 0.010 |
Why?
|
| Pneumothorax | 1 | 1982 | 76 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1984 | 495 | 0.010 |
Why?
|
| Coronaviridae | 1 | 1998 | 4 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 1999 | 86 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2824 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 144 | 0.010 |
Why?
|
| Urban Health | 1 | 1998 | 78 | 0.010 |
Why?
|
| Rhinovirus | 1 | 1998 | 59 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1984 | 1377 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1998 | 51 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1999 | 317 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 2434 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 658 | 0.010 |
Why?
|
| Technology Transfer | 1 | 1997 | 8 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1998 | 480 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1727 | 0.010 |
Why?
|
| Age Factors | 2 | 1994 | 2831 | 0.010 |
Why?
|
| Kidney | 1 | 1983 | 1369 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1998 | 1296 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1996 | 267 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1997 | 383 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1996 | 342 | 0.010 |
Why?
|
| Tissue Fixation | 1 | 1995 | 38 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1998 | 1333 | 0.010 |
Why?
|
| Ventilators, Mechanical | 2 | 1984 | 40 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1995 | 187 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1994 | 166 | 0.010 |
Why?
|
| Peptic Ulcer | 1 | 1995 | 150 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 1995 | 254 | 0.010 |
Why?
|
| Macrophages, Alveolar | 1 | 1993 | 49 | 0.010 |
Why?
|
| Resuscitation Orders | 1 | 1993 | 32 | 0.010 |
Why?
|
| American Hospital Association | 1 | 1992 | 3 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 1154 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1992 | 51 | 0.010 |
Why?
|
| Patient Transfer | 1 | 1993 | 105 | 0.010 |
Why?
|
| Allied Health Personnel | 1 | 1992 | 72 | 0.010 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1992 | 91 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1992 | 122 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 1992 | 166 | 0.010 |
Why?
|
| Survival Rate | 1 | 1996 | 2073 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1994 | 1248 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1992 | 132 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 1278 | 0.010 |
Why?
|
| Neoplasms | 1 | 1984 | 2803 | 0.010 |
Why?
|
| Random Allocation | 1 | 1987 | 441 | 0.000 |
Why?
|
| Phenotype | 1 | 1995 | 4273 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1984 | 189 | 0.000 |
Why?
|
| Postoperative Period | 1 | 1984 | 335 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1983 | 129 | 0.000 |
Why?
|
| Infant | 1 | 1993 | 12572 | 0.000 |
Why?
|